InoCardia has secured the investment from Mercia Fund Management.
InoCardia, a spin-out from Coventry University offering drug screening services, has secured a £229,000 ($340,000) investment from Mercia Fund Management.
The cash injection will allow InoCardia to develop and commercialise its pre-clinical drug testing service, which it is aiming at pharmaceutical companies. The technology is based on ten years of research conducted by Helen Maddock at the university’s Centre for Applied Biological and Exercise Sciences.
The technology works by mimicking the biomechanical performance of a cardiac muscle, letting drug developers…
